Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
LATEST NEWS
- Empagliflozin Potentially Protects Pancreatic Beta-cells in T1DM
- Use of SGLT-2 Inhibitors Combo with Metformin for Greater Glycemic Control
- Empagliflozin: Potential New Approach to Treating T2DM
EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners
Editor's Note
On Tuesday in our DCMS issue, I spoke about a newly diagnosed type 1 patient and the anxiety his family was experiencing. I asked for an Endo in the Raleigh, NC area and many of you offered a suggestion. The family followed the recommendation of our good friend Dr. John Buse. Hopefully this young man will get the care and training he needs to manage his diabetes for many years to come. One of the ways he may be able to increase his control is by using an SGLT-2 inhibitor. This month our special edition looks at the possibility that using an SGLT-2 inhibitor can preserve and possibly rejuvenate beta cells in type 1 patients.
Your partner in diabetes care,
Dave Joffe
Editor-in-chief
Latest News
New animal study shows the effects of empagliflozin, an SGLT-2 inhibitor, on the pancreatic cells of mice.
Is there actual benefit in dual therapy treatment?
Empagliflozin is proving to be a strong proponent for monotherapy in patients with T2DM.
Exclusive Interview
In part 3 of this Exclusive Interview, Dr. Rhinehart shares his thoughts with DIC publisher Steve Freed on the benefits of SGLT-2 and GLP-1s. What do these new medications offer when it comes to costs, side effects and staying on top of the research to help facilitate use in the right patients?